ImmunoGen, Inc. (NASDAQ:IMGN) Q4 2022 Earnings Call Transcript

Peter Lawson: Got it. Thank you. And I’m sure property been through before. But just around the change in the guidance in MIRASOL from early ’23 to 2Q. Any kind of technical reasons around that? Or was it kind of a longer-than-expected time frame to gain PFS events?

Anna Berkenblit: Yes. So slightly longer period to get the PFS events we originally had guided to before the end of December in 2022, and now we’re imminent. So our models are as good as they can be. And clearly, our models weren’t perfect. And there’s other reasons you could speculate. Maybe the patients on mirvetuximab are doing a bit better. Maybe the patients on IC chemo are doing a little bit better. Maybe all of the patients are doing a little bit better, and maybe there’s a combination of all of these factors. So I don’t know, not worried. Imminently, we will trigger the final PFS analysis.

Peter Lawson: Great. Thanks so much.

Operator: Thank you. This concludes the Q&A session. I would now like to hand the conference back over to the team for closing remarks.

Mark Enyedy: Great. Well, thank you very much for joining us today. As you can hear from the comments here, there’s a lot of excitement for the business as we come into 2023 and look at the year ahead. The launch is exceeding our expectations, and we have a number of important readouts upcoming, so look forward to talking to you as we work through those data and report out subsequent earnings. So thanks very much.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.